Objectives To assess the performance of non-invasive prenatal testing (NIPT) 
INTRODUCTION
Achondroplasia is the most common non-lethal chondrodysplasia, with an estimated rate of around 1 in 20 000 live births 1 , and affects about 250 000 people worldwide. It is an autosomal dominant disorder with complete penetrance, and is caused in more than 99% of those affected by one of two pathogenic variants in the fibroblast growth factor receptor 3 gene (FGFR3), namely c.1138G > A and c.1138G > C, resulting in a single amino acid change p.Gly380Arg (G380R). If prenatal diagnosis is requested in the case of a high-risk pregnancy, it is usually performed very early during pregnancy, using genetic analysis of chorionic villus samples or amniotic cells collected by an invasive procedure. However, approximately 80% of cases are due to a de-novo mutation 2 , meaning that most cases of achondroplasia appear in what are theoretically low-risk pregnancies. Achondroplasia can be suggested prenatally by the presence of relatively non-specific sonographic features 3 . Identification of short fetal limbs during the late second trimester or third trimester remains the cornerstone of diagnosis of achondroplasia 4 . Nevertheless, diagnosis of this rare disease remains uncertain in some cases, and a three-dimensional (3D) computed tomography (CT) prenatal scan may be helpful 5, 6 . Molecular confirmation by invasive procedures might also be required, leading to a theoretical risk of miscarriage or preterm prelabor rupture of membranes of 0.1% to 0.2% 7 .
Since Lo et al. 8 described the presence of cell-free fetal DNA (cffDNA) in the plasma of pregnant women, many applications have been developed, including the prenatal diagnosis of achondroplasia, which served as a model for single-gene disorders suited to the development of a non-invasive detection procedure 9 . As most cases of achondroplasia result from a de-novo mutation, the maternal DNA 'background' does not interfere with the qualitative detection of the specific mutation in the maternal plasma. Different methodologies have been used for the non-invasive prenatal testing (NIPT) of achondroplasia, usually in single cases or small series, all of them retrospective [10] [11] [12] [13] [14] . We report here the results of a novel simple non-invasive molecular analysis technique using high-resolution melting (HRM) analysis for the prenatal diagnosis of achondroplasia in a prospective multicenter cohort of pregnant women with a fetus at risk for skeletal dysplasia. A new diagnostic strategy for fetal achondroplasia combining ultrasound (US) biometric findings and cffDNA analysis is proposed.
PATIENTS AND METHODS

Study population
This was a prospective study of 151 pregnant women enrolled at 31 prenatal diagnosis centers in France between September 2009 and January 2016 (Figure 1 ). Eighty-six were enrolled consecutively because of a high risk of fetal achondroplasia (patient group) related to a short long bone (below the 3 rd percentile) on US examination in the second or third trimester of pregnancy (n = 79), a history of pregnancy with a de-novo affected fetus (n = 4), or because the father was affected by achondroplasia (n = 3). All except two were singleton pregnancies. Women were offered cffDNA analysis for achondroplasia at the time of US examination. Median maternal age was 33 (range, 18-45) years and median gestational age (GA) at entry to the study was 32 (range, 12-37) weeks. The diagnosis of achondroplasia was confirmed or excluded by molecular analysis of the fetus after an invasive procedure (amniocentesis), 3D-CT antenatal scan, histopathological examination of the fetus in the case of termination of pregnancy or by clinical examination of the newborn by pediatricians at birth. If chondrodysplasia was suspected after postnatal examination, molecular FGFR3 analysis was performed to confirm the diagnosis.
Sixty-five healthy women with a normal singleton pregnancy at the third-trimester US examination were also enrolled consecutively as controls. Median maternal age in the control group was 34 (range, 22-48) years and median GA at entry to the study was 33 (range, 27-38) weeks.
Ultrasound examination
Prenatal US examinations were performed by referral operators at 31 French antenatal diagnosis or obstetric units, according to Collège National des Gynécologues et Obstétriciens Français and Comité Technique de l'Echographie guidelines. Conception dates used to calculate GA were based on first-trimester crown-rump length reported on a Robinson curve 15 .
Blood sample preparation
Maternal blood samples were collected into cffDNA BCT Streck ® tubes (10 mL) or ethylenediaminetetraacetic acid (EDTA) tubes (5 mL) with a neutral solution of formaldehyde (1 mL/L final concentration) prepared as described previously 16 . Less than 72 h after blood sampling, each tube was centrifuged at 3000 g for 10 min at room temperature and the plasma was then stored immediately at −80 • C. Total plasma DNA was extracted from 1 mL of plasma using the MagNapure Compact Nucleic Isolation Kit (Roche Diagnostics, Meylan, France) according to the manufacturer's guidelines, the adsorbed DNA being eluted with 50 μL of elution buffer. Each maternal plasma sample was extracted twice and all reactions were performed in duplicate. In parallel, genomic DNA was extracted from standard EDTA whole blood from the mother and the father using the Chemagen DNA blood kit on the JANUS Automated Workstation (Perkin-Elmer, Courtaboeuf, France).
FGFR3 mutation and paternal single nucleotide polymorphism detection in maternal plasma
HRM polymerase chain reaction (HRM-PCR) is an efficient and sensitive tool for the detection of mutations, not only in oncology but also in NIPT [17] [18] [19] . We therefore decided to apply this strategy for the first time to achondroplasia. DNA extracted from maternal plasma was amplified using real-time PCR targeted to the region of the FGFR3 gene containing the G380R variant followed by HRM and analysis of the corresponding melting curve, with differences in the melting-curve shapes revealing the presence of the G380R mutated allele in the maternal plasma. Amplification was carried out in a similar manner to that described previously 20 . In the case of a negative result for the G380R variant, the capability of the method to detect a fetal variant (and as a consequence the presence of fetal DNA in maternal plasma) was evaluated through the detection of at least one other paternally inherited variant using the same PCR-HRM method, according to a strategy similar to that of Chen et al. 21 . One set of primers was therefore designed specifically to amplify 13 single nucleotide polymorphisms (SNPs) located in different regions of the genome. This panel of SNPs was selected for their high level of heterozygosity. After identification of SNP loci for which the pregnant woman was homozygous and that differed from the father's, plasma samples were analyzed for these non-maternal alleles to confirm the presence and, above all, the inhibitory effect of DNA extracts. In addition, owing to the non-specific nature of the method, all positive or ambiguous melting-curve profiles were confirmed systematically by a second sequence-specific confirmation approach based on minisequencing. Briefly, following purification of the PCR products using ExoSAPIT (USB Europe, Staufen, Germany), SNaPshot analysis was carried out using the SNaPshot Multiplex kit (Applied Biosystems, Courtaboeuf, France) and the reactions were run on an ABI3130XL genetic analyzer and analyzed using Genescan software (Applied Biosystems, Courtaboeuf, France). HRM and SNaPshot minisequencing sensitivities are reported in Figure 2 .
Statistical analysis
Z-scores for femur length and head circumference were calculated using Altman and Chitty's curves 22 : Z-score = (x -mean)/SD. For head circumference, mean = -109.7 + (15.16 × GA) -(0.002388 × GA 3 ) and SD= 3.913 + (0.2329 × GA). For femur length, mean = -32.43 + (3.416 × GA) -(0.0004791 × GA 3 ) and SD = 1.06 + (0.05833 × GA).
Statistical analysis was performed using the non-parametric Mann-Whitney U-test for quantitative variables; P < 0.05 was considered to indicate statistical significance.
A decision tree was produced that can be used to guide the diagnosis of affected fetuses, while avoiding the routine use of cffDNA analysis for achondroplasia, as it is a highly specialized and costly assay, and limiting the use of CT scans. This algorithm takes into account the cffDNA test results and US biometric and morphological findings. Femoral length Z-score thresholds were established retrospectively in order to limit the number of unnecessary non-invasive tests (true-negative tests) while identifying the majority of affected fetuses.
This study was approved by the institutional review board CPP ILE DE FRANCE II (2009-154). All data were anonymized to ensure patient privacy and confidentiality. In line with French regulations regarding prenatal diagnosis, written informed consent was obtained from all patients.
RESULTS
Non-invasive prenatal testing for achondroplasia
Of the 151 pregnant women in the study (median GA, 32.7 ± 4.5 (range, 11.6-38.6) weeks), 33 were positive for fetal achondroplasia (31 with the G > A variant, two with the G > C variant), two of the pregnancies being twin gestations (dichorionic-diamniotic). All the positive results were in high-risk patients (31 with US findings, two with an affected father) and were consistent with antenatal findings on 3D-CT scan (n = 15) and/or DNA analysis of the fetus after an invasive procedure (n = 14), when performed, and/or clinical examination at birth (n = 32). Ten terminations of pregnancy were performed in accordance with French law. All other high-risk patients were negative for the FGFR3 variant and none of the fetuses was affected by achondroplasia. None of the 65 patients in the control group had a positive cffDNA assay. Three cases of Down syndrome were diagnosed prenatally in the control group, all of which were terminated. The results of the pediatric examination at birth were normal in all control pregnancies. There were no false-positive or false-negative cffDNA results, and sensitivity and specificity were 1.00 (95% CI, 0.87-1.00) and 1.00 (95% CI, 0.96-1.00), respectively.
For three patients, analysis of cell-free DNA by HRM showed an abnormal melting curve, but a pathogenic FGFR3 variant was not confirmed on minisequencing. Conventional sequencing of the mother's genomic DNA demonstrated that these patients were carriers of the benign variant c.1150 T > C (p.Phe384Leu), thus demonstrating the absolute necessity of confirming any abnormal HRM result. Additionally, for 23 patients who were negative for a FGFR3 variant, the presence of paternally derived SNPs could not be demonstrated definitively either because a paternal blood sample was not available (n = 12) or because none of the 13 SNP studies was informative (n = 11).
Ultrasound biometric findings
Analysis of second-trimester US examinations (median GA, 22.3 weeks) showed a significantly shorter femur in fetuses tested for achondroplasia with a negative cffDNA result in comparison with those with a positive result (femur length Z-scores of -1.5 ± 1.2 vs -1.0 ± 1.2, respectively; P = 0.03) ( Table 1 and Figure 3a) . At the last US examination (median GA, 32.3 weeks), fetuses with achondroplasia exhibited critical shortening of the femur compared with those with suspected short long bones but unaffected by achondroplasia (Z-scores of -5.0 ± 1.5 and -3.0 ± 1.2, respectively; P < 0.0001) ( Table 1 and Figure 3b ). Linear regression curves for femur length in the 'cffDNA-negative' and 'cffDNA-positive' subgroups crossed at 25.6 weeks' gestation ( Figure 4 ). There was no difference in head circumference at the second-trimester US examination. However, head circumference at the last US examination tended to be higher in fetuses in the patient group in comparison to controls (Z-score of 0.4 ± 1.3 vs -0.7 ± 1.0; P < 0.001). In the patient group, there was no difference in head circumference between 'negative-test' and 'positive-test' subgroups.
Decision tree
In order to diagnose fetuses affected by achondroplasia, we considered the following combined strategy ( Figure 5 ). Any woman carrying a fetus with rhizomelic shortening bowing and/or trident hand. If there was one such additional sign, cffDNA analysis was offered. If rhizomelic shortening was isolated (femoral length Z-score ≤ -2), the US examination was repeated at 26 weeks or later and cffDNA analysis could be offered in the case of worsening. After 26 weeks' gestation, a femur length Z-score threshold of -4 was used. At this cut-off, 80% of the affected fetuses would have been tested on the basis of only biometric findings. The other 20% would have been tested because of typical morphological signs. Indeed, this test would not have been proposed for 75% of negative patients when using a femur length Z-score threshold of -4. In both situations, if diagnosis of achondroplasia was not confirmed on cffDNA analysis, a CT scan could be considered after 28 weeks, along with an invasive procedure for array comparative genomic hybridization analysis or any other investigations to help make a differential diagnosis (diagnosis of other skeletal dysplasia) ( Figure 5 ).
DISCUSSION
We report here a simple new approach to the non-invasive diagnosis of achondroplasia based on cffDNA analysis using HRM-PCR technology combined with minisequencing. This cffDNA approach was highly accurate in 151 pregnant women, 86 of whom were at high risk of carrying a fetus affected by achondroplasia. cffDNA analysis detected the paternally inherited or de-novo pathogenic variant leading to an achondroplasia phenotype in 33 fetuses. Sensitivity and specificity were 1.00 (95% CI, 0.87-1.00) and 1.00 (95% CI, 0.96-1.00), respectively. Combined with US biometric and morphological findings, cffDNA analysis thus offers a new aid in the non-invasive prenatal diagnosis of achondroplasia. NIPT for monogenic disorders is quite challenging owing, in part, to the low level of cffDNA but, above all, to extreme dilution of cffDNA in the background of maternal DNA in plasma 23 and because there is no possibility of specifically purifying that fetal DNA. HRM-PCR, which can detect single-base variation in a specific PCR amplicon, has been used extensively in oncology, as it is able to detect minority alleles very accurately at a lower cost, without the need for expensive specialist equipment. HRM-PCR has been evaluated already in the prenatal determination of several monogenic diseases. Yenilmez et al. 17 successfully detected paternally inherited fetal mutations responsible for β-thalassemia. All results were consistent with the genotypes obtained using conventional techniques, while HRM-PCR reduced the time needed from 3 days to 1 day. These results were recently confirmed by Zafari et al. 19 . Combined with co-amplification at lower denaturation-temperature PCR, HRM is more sensitive than is conventional PCR for the detection of very-low-level mutations 24 and has been applied with very promising results to non-invasive determination of the fetal HPA-1 genotype by Ferro et al. 18 in the context of fetal-maternal platelet incompatibility. Macher et al. 25 successfully used the same technical procedure for the non-invasive diagnosis of multiple endocrine neoplasia type 2A.
Multiple other approaches to NIPT for achondroplasia have been evaluated, based on conventional PCR with restriction enzymes as a detection format 26 , matrix-assisted laser desorption ionization time-of-flight mass spectrometry, real-time quantitative PCR, digital PCR or, more recently, next-generation sequencing [11] [12] [13] [14] . None, however, met the criteria of high sensitivity, lower possibility of DNA contamination, reduced hands-on time and need for technical expertise, rapid turnaround time for reporting and cost-effectiveness, especially in terms of specialist equipment requirements. Digital PCR is an attractive technology but, to date, has had limited clinical validation. In a single retrospective cohort of 26 fetuses at risk for achondroplasia, Orhant et al. 14 reported 100% sensitivity and 100% specificity but with only five positive results. On the other hand, next-generation sequencing has been assessed but it seems to be ill-suited to prenatal diagnosis of rare diseases because of the number of samples vs the need for a very short turnaround time, leading to a high cost per run, which limits its use in clinical laboratories 13 . HRM-PCR therefore appeared to be a good compromise.
Notwithstanding the test's accuracy and simplicity of use, it is important to define which patients could benefit from NIPT in order to avoid unnecessary prescription. US biometric and morphological analysis showed that achondroplasia usually cannot be suspected until the middle of the second trimester. Critical reduction in femur length in affected fetuses can be observed after 26 weeks' gestation. The group of patients with a negative achondroplasia test comprised patients with heterogeneous clinical conditions; most of them were affected by severe intrauterine growth restriction, which can impact on femoral length. Rhizomelic micromelia could be accompanied by other US features, such as frontal bossing, relative macrocephaly, depressed nasal bridge, limb bowing and trident hand. In our cohort, the presence of relative macrocephaly did not improve the detection of achondroplasia. US signs for achondroplasia have low specificity, although more specific signs, such as an abnormal connection between the femoral diaphysis and metaphysis with overgrowth of the periosteum ('collar hoop' sign), have been described 6 . The advantage of 3D over two-dimensional imaging is moderate, although it can specify the extent of the disproportion between rhizomelic bones, the trunk and the head 27 . The accuracy of diagnosis of achondroplasia could be improved dramatically by a late CT scan, but its use during pregnancy is controversial 28 . Indeed, avoiding radiation is a public health issue, especially during pregnancy, so it is essential to promote the use of examinations that do not involve exposure to radiation.
In order to provide a cost-effective non-invasive strategy for the diagnosis of fetal achondroplasia during the second and third trimesters, we designed an algorithm that took into account US biometric and morphological findings as well as cffDNA results ( Figure 5 ). cffDNA could be proposed at any GA, even in the first trimester, for the management of healthy pregnant women with an identified pre-existing risk factor, such as a history of an affected pregnancy, or for a pregnancy in which the father is affected. Unfortunately, at the moment, for technical reasons it cannot be applied to pregnant women who are affected by the disease, as their plasma contains a background of mutated DNA.
In conclusion, HRM-PCR combined with US is a reliable and cost-effective approach to the non-invasive testing for achondroplasia. The strategy could be extended to differential diagnosis between achondroplasia and hypochondroplasia.
